Evidence map›Paper›PMID 25834211›Full record

ArticleThe Journal of rheumatology2015

Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing.

Deepak A Rao, Kevin Wei, Joseph F Merola, William R O'Brien, Samuel U Takvorian, Paul F Dellaripa, Peter H Schur

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Case reports in nephrology · 2018
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Deepak A RaoFrom the Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts, USA.D.A. Rao, MD, PhD, Fellow in Rheumatology; K. Wei, MD, PhD, Fellow in Rheumatology; W.R. O'Brien, Fellow in Rheumatology; S.U. Takvorian, MD, Resident in Internal Medicine; P.F. Dellaripa, MD, Assistant Professor of Medicine; P.H. Schur, MD, Professor of Medicine, Brigham and Women's Hospital; J.F. Merola, MD, Instructor, Harvard Medical School.
Kevin WeiFrom the Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts, USA.D.A. Rao, MD, PhD, Fellow in Rheumatology; K. Wei, MD, PhD, Fellow in Rheumatology; W.R. O'Brien, Fellow in Rheumatology; S.U. Takvorian, MD, Resident in Internal Medicine; P.F. Dellaripa, MD, Assistant Professor of Medicine; P.H. Schur, MD, Professor of Medicine, Brigham and Women's Hospital; J.F. Merola, MD, Instructor, Harvard Medical School.
Joseph F MerolaFrom the Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts, USA.D.A. Rao, MD, PhD, Fellow in Rheumatology; K. Wei, MD, PhD, Fellow in Rheumatology; W.R. O'Brien, Fellow in Rheumatology; S.U. Takvorian, MD, Resident in Internal Medicine; P.F. Dellaripa, MD, Assistant Professor of Medicine; P.H. Schur, MD, Professor of Medicine, Brigham and Women's Hospital; J.F. Merola, MD, Instructor, Harvard Medical School.
William R O'BrienFrom the Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts, USA.D.A. Rao, MD, PhD, Fellow in Rheumatology; K. Wei, MD, PhD, Fellow in Rheumatology; W.R. O'Brien, Fellow in Rheumatology; S.U. Takvorian, MD, Resident in Internal Medicine; P.F. Dellaripa, MD, Assistant Professor of Medicine; P.H. Schur, MD, Professor of Medicine, Brigham and Women's Hospital; J.F. Merola, MD, Instructor, Harvard Medical School.
Samuel U TakvorianFrom the Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts, USA.D.A. Rao, MD, PhD, Fellow in Rheumatology; K. Wei, MD, PhD, Fellow in Rheumatology; W.R. O'Brien, Fellow in Rheumatology; S.U. Takvorian, MD, Resident in Internal Medicine; P.F. Dellaripa, MD, Assistant Professor of Medicine; P.H. Schur, MD, Professor of Medicine, Brigham and Women's Hospital; J.F. Merola, MD, Instructor, Harvard Medical School.
Paul F DellaripaFrom the Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts, USA.D.A. Rao, MD, PhD, Fellow in Rheumatology; K. Wei, MD, PhD, Fellow in Rheumatology; W.R. O'Brien, Fellow in Rheumatology; S.U. Takvorian, MD, Resident in Internal Medicine; P.F. Dellaripa, MD, Assistant Professor of Medicine; P.H. Schur, MD, Professor of Medicine, Brigham and Women's Hospital; J.F. Merola, MD, Instructor, Harvard Medical School. pschur@partners.org pdellaripa@partners.org.
Peter H SchurFrom the Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital; Harvard Medical School, Boston, Massachusetts, USA.D.A. Rao, MD, PhD, Fellow in Rheumatology; K. Wei, MD, PhD, Fellow in Rheumatology; W.R. O'Brien, Fellow in Rheumatology; S.U. Takvorian, MD, Resident in Internal Medicine; P.F. Dellaripa, MD, Assistant Professor of Medicine; P.H. Schur, MD, Professor of Medicine, Brigham and Women's Hospital; J.F. Merola, MD, Instructor, Harvard Medical School. pschur@partners.org pdellaripa@partners.org.
Brigham and Women's Hospital · USHarvard University · US

Funding

MECHANISMS OF ARTHRITIC &DERMATOLOGY DISORDERST32AR007530 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Michael B. Brenner, Ellen M Gravallese · 1986 to 2026
$10.4M
NIAMS NIH HHS T32 5T32AR007530NIAMS NIH HHS T32 AR007530
6 · The paper itself

Abstract

objectiveConcurrent testing for serum antineutrophil cytoplasmic antibodies (ANCA) by indirect immunofluorescence (IF) and by antiproteinase 3 (PR3)/antimyeloperoxidase (MPO) antibody assays may identify patients with PR3-ANCA or MPO-ANCA despite a negative IF (IF-negative MPO/PR3-positive); however, the significance of this result is not clear. We sought to determine whether IF-negative, MPO/PR3-positive results identified any cases of clinically meaningful systemic vasculitis at our institution.

methodsWe conducted a retrospective chart review of all IF-negative, MPO/PR3-positive patients identified at our institution over a 2-year period.

resultsOf the 2345 samples tested over 2 years, 1998 were IF-negative. Among these IF-negative samples, 49 samples (2.5%) derived from 38 patients tested positive for MPO-ANCA or PR3-ANCA. Only 1 IF-negative, MPO/PR3-positive patient was subsequently diagnosed with ANCA-associated vasculitis (AAV). Eleven IF-negative, MPO/PR3-positive patients (29%) had been previously diagnosed and treated for AAV, all with positive IF and antibody tests prior to treatment. Four patients had evidence of cutaneous vasculitis not attributed to AAV, while several of the remaining IF-negative, MPO/PR3-positive patients had other immunologic disorders, including systemic lupus erythematosus (5 patients) and inflammatory bowel disease (3 patients).

conclusionIn this real-life cohort assayed simultaneously by IF and multiplexed bead assays, the detection of MPO-ANCA or PR3-ANCA without a positive IF rarely led to a new diagnosis of systemic vasculitis, and was more likely to occur in the context of a non-vasculitic inflammatory condition. Our results suggest that concurrent IF and MPO/PR3 testing may be of limited use in preventing a missed diagnosis of new-onset AAV.

Indexed as

AdultAgedAged, 80 and overAntibodies, Antineutrophil CytoplasmicFemaleFluorescent Antibody Technique, IndirectHumansMaleMiddle AgedMyeloblastinPeroxidaseRetrospective StudiesSystemic VasculitisYoung AdultAntibodies, Antineutrophil CytoplasmicMyeloblastinPeroxidaseANTINEUTROPHIL CYTOPLASMIC ANTIBODIESOUTCOMESVASCULITIS

Identifiers

PMID25834211
PMCPMC5319927
OpenAlexW2044252846

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.